RAB11FIP4

Across TCGA pan-cancer cohorts, RAB11FIP4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RAB11FIP4 data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RAB11FIP4 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated RAB11FIP4 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LUAD, CCRCC, and PDAC are the cancer types where RAB11FIP4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.865	0.412	<.001	41	view →
CCRCC	OS	Median	IV	1.000	0.451	.016	20	view →
PDAC	OS	Median	III,IV	0.919	0.599	.013	13	view →
LSCC	OS	Median	All	0.931	1.000	.009	9	view →
HNSC	DFS	Quartile	IV	0.555	0.918	.020	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RAB11FIP4–LUAD (OS)

Open the LUAD breakdown →